Stockreport

AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis

AVROBIO, Inc.  (AVRO) 
Last avrobio, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.avrobio.com/investor-relations
PDF CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that it [Read more]